Classement en actions
#29740
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to... Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Prix de l'action
$3.14
Dernière synchronisation: 2026-08-18
Capitalisation boursière
$19.83M
Changement (1 jour)
0.32%
Échange Evaxion Biotech A/S (EVAX)
Le prix EVAX avec la capitalisation boursière de B
Capitalisation boursière de Evaxion Biotech A/S(EVAX)
Capitalisation boursière: $19.83M
En August 2026, Evaxion Biotech A/S a une capitalisation boursière de $19.83M. Cela fait de Evaxion Biotech A/S la 29740th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Evaxion Biotech A/S du 2021 au 2026
EVAX par rapport au top 5 des plus populaires stocks
| Prix pour EVAX |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.307T
|
+26,754,815.74%
|
|
|
|
|
$4.551T
|
+22,943,949.74%
|
|
|
|
|
$4.154T
|
+20,945,524.83%
|
|
|
|
|
$3.589T
|
+18,092,768.75%
|
|
|
|
|
$2.797T
|
+14,101,147.13%
|
